GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function

OBJECTIVE: GPR142 agonists are being pursued as novel diabetes therapies by virtue of their insulin secretagogue effects. But it is undetermined whether GPR142's functions in pancreatic islets are limited to regulating insulin secretion. The current study expands research on its action. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hua V., Wang, Jingru, Wang, Jie, Li, Weiji, Wang, Xuesong, Alston, James T., Thomas, Melissa K., Briere, Daniel A., Syed, Samreen K., Efanov, Alexander M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001353/
https://www.ncbi.nlm.nih.gov/pubmed/29506910
http://dx.doi.org/10.1016/j.molmet.2018.02.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001353/
https://www.ncbi.nlm.nih.gov/pubmed/29506910
http://dx.doi.org/10.1016/j.molmet.2018.02.008

Ejemplares similares